Nanjing Well Pharmaceutical Group (603351) Fair Value & Analysis
Healthcare · CN · Market cap 3.4B CNY
Analysis
Nanjing Well Pharmaceutical Group (603351) currently trades at ¥24.64, while our model-based Fair Value estimate is ¥24.52 — implying the stock looks roughly 0.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China. It is involved in the bio-based material manufacturing, sales, and technology development; technical development and consulting; bio-based material technology research and development; biochemical product technology research and development; food and food additive production and sales; and research and development of new material technologies, as well as provides technical services; and manufactures and sells electronic materials. The company also exports its products to Europe, the United States, Southeast Asia, and internationally. The company was formerly known as Nanjing Well Pharmaceutical Co.,Ltd. and changed its name to Nanjing Well Pharmaceutical Group Co.,Ltd. in April 2020. Nanjing Well Pharmaceutical Group Co.,Ltd. was founded in 2000 and is based in Nanjing, China.
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.